EE200200484A - Väikeseannuseline entekaviiripreparaat ja selle kasutamine - Google Patents

Väikeseannuseline entekaviiripreparaat ja selle kasutamine

Info

Publication number
EE200200484A
EE200200484A EEP200200484A EEP200200484A EE200200484A EE 200200484 A EE200200484 A EE 200200484A EE P200200484 A EEP200200484 A EE P200200484A EE P200200484 A EEP200200484 A EE P200200484A EE 200200484 A EE200200484 A EE 200200484A
Authority
EE
Estonia
Prior art keywords
low dose
dose entecavir
preparation
entecavir preparation
low
Prior art date
Application number
EEP200200484A
Other languages
English (en)
Inventor
J. Colonno Richard
L. Sprockel Omar
Harianawala Abizer
S. Desai Divyakant
G. Fakes Michael
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26881354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200200484(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of EE200200484A publication Critical patent/EE200200484A/et
Publication of EE05442B1 publication Critical patent/EE05442B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
EEP200200484A 2000-02-29 2001-01-26 V„ikeses annuses entekaviiri sisaldav ravimkoostis B-hepatiidi viirusinfektsiooni raviks ning meetod selle valmistamiseks EE05442B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18567200P 2000-02-29 2000-02-29
US22131300P 2000-07-28 2000-07-28
PCT/US2001/002630 WO2001064221A1 (en) 2000-02-29 2001-01-26 Low dose entecavir formulation and use

Publications (2)

Publication Number Publication Date
EE200200484A true EE200200484A (et) 2004-04-15
EE05442B1 EE05442B1 (et) 2011-08-15

Family

ID=26881354

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200484A EE05442B1 (et) 2000-02-29 2001-01-26 V„ikeses annuses entekaviiri sisaldav ravimkoostis B-hepatiidi viirusinfektsiooni raviks ning meetod selle valmistamiseks

Country Status (35)

Country Link
US (1) US6627224B2 (et)
EP (2) EP1267880B2 (et)
JP (3) JP5140222B2 (et)
KR (1) KR100757155B1 (et)
AR (1) AR027965A1 (et)
AT (1) ATE312613T1 (et)
AU (1) AU2001229775A1 (et)
BG (1) BG65815B1 (et)
BR (1) BRPI0108435B8 (et)
CA (1) CA2401569C (et)
CO (1) CO5261593A1 (et)
CZ (1) CZ303395B6 (et)
DE (1) DE60115870T3 (et)
DK (1) DK1267880T4 (et)
EA (1) EA006181B1 (et)
EE (1) EE05442B1 (et)
EG (1) EG24408A (et)
ES (1) ES2253403T5 (et)
GE (1) GEP20053504B (et)
HK (1) HK1048771A1 (et)
HR (1) HRP20020649A2 (et)
HU (1) HU230698B1 (et)
IL (1) IL150447A0 (et)
MX (1) MXPA02008359A (et)
MY (1) MY127422A (et)
NO (1) NO324014B1 (et)
NZ (1) NZ520024A (et)
PE (1) PE20020770A1 (et)
PL (1) PL201411B1 (et)
RS (1) RS51561B (et)
SI (1) SI1267880T2 (et)
SK (1) SK288008B6 (et)
TW (1) TWI287988B (et)
UA (1) UA84534C2 (et)
WO (1) WO2001064221A1 (et)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150447A0 (en) * 2000-02-29 2002-12-01 Bristol Myers Squibb Co Pharmaceutical compositions containing entecavir
TWI275392B (en) * 2002-04-08 2007-03-11 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
IN2012DN00606A (et) 2002-12-11 2015-06-12 Bristol Mayers Squibb Company
ATE398455T1 (de) 2003-01-14 2008-07-15 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
EP1708690B1 (en) 2003-11-17 2016-07-20 BioMarin Pharmaceutical Inc. Treatment of phenylketonuria with bh4
KR20060125805A (ko) * 2003-11-18 2006-12-06 베링거 인겔하임 인터내셔날 게엠베하 고체 약제학적 제제 형태
US7511139B2 (en) * 2004-06-04 2009-03-31 Bristol-Myers Squibb Company Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
JP4756153B2 (ja) * 2004-08-27 2011-08-24 富士製薬工業株式会社 低成分含量の錠剤の製造方法
WO2006034397A2 (en) * 2004-09-23 2006-03-30 Fmc Corporation Coating composition
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
CN101245068A (zh) * 2007-02-14 2008-08-20 浙江医药股份有限公司新昌制药厂 结晶型态的恩替卡韦及其制备方法和其药物组合物及用途
PE20090185A1 (es) 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
CA2778273A1 (en) 2009-10-28 2011-05-12 Mcneil-Ppc, Inc. Fast dissolving/disintegrating coating compositions
WO2011076412A1 (de) 2009-12-23 2011-06-30 Ratiopharm Gmbh Orale darreichungsform umfassend entecavir
DE102009060194A1 (de) 2009-12-23 2011-06-30 ratiopharm GmbH, 89079 Orale Darreichungsform umfassend Entecavir
WO2011103516A2 (en) * 2010-02-18 2011-08-25 The Trustees Of Princeton University Inhibitors of long and very long chain fatty acid metabolism as broad spectrum anti-virals
CN102892291A (zh) 2010-03-31 2013-01-23 米伦纽姆医药公司 1-氨基-2-环丙基乙硼酸衍生物
WO2012048455A1 (zh) * 2010-10-12 2012-04-19 武汉大学 一种抗病毒透皮吸收贴片及其制备方法
EP2508172A1 (en) 2011-04-06 2012-10-10 Zentiva, a.s. Stable and uniform formulations of entecavir and preparation method thereof
KR101594820B1 (ko) * 2011-06-16 2016-02-17 건일제약 주식회사 엔테카비르를 함유하는 미립구 및 이의 제조방법
KR101439635B1 (ko) 2011-11-01 2014-09-11 대원제약주식회사 안정성이 향상된 엔테카비어를 함유하는 약학적 조성물 및 그 제조방법
US20140315930A1 (en) * 2011-11-14 2014-10-23 Hetero Research Foundation Fast release solid oral compositions of entecavir
EP2644196B1 (en) * 2012-03-26 2019-09-18 Arven Ilac Sanayi ve Ticaret A.S. Pharmaceutical compositions of Entecavir
EP2644197A1 (en) * 2012-03-26 2013-10-02 Sanovel Ilac Sanayi ve Ticaret A.S. Novel Pharmaceutical Compositions of Entecavir
KR101285008B1 (ko) * 2012-04-18 2013-07-10 제일약품주식회사 저용량 엔테카비어의 경구투여 제제의 제조방법
CA2779052A1 (en) * 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
CN103908436B (zh) * 2012-12-29 2016-02-10 安徽贝克生物制药有限公司 一种速释型恩替卡韦组合物
KR101512895B1 (ko) 2013-08-09 2015-04-16 대화제약 주식회사 엔테카비어를 포함하는 약학적 조성물의 제조방법
CN106573003B (zh) * 2014-06-20 2022-04-01 西梯茜生命工学股份有限公司 含有恩替卡韦作为活性成分的药物制剂及其制备方法
EP3357515A4 (en) 2015-09-30 2019-06-19 Daicel Corporation COMPOSITION FOR SOLID PREPARATION EASY TO USE, EASY SOLID PREPARATION FOR USE COMPRISING SAID PARTICLE COMPOSITION
KR20230112817A (ko) 2022-01-21 2023-07-28 한림대학교 산학협력단 피루브산 및 pdk 억제제를 포함하는 뇌질환의 예방 또는 치료용 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3836618A (en) * 1971-12-23 1974-09-17 American Home Prod Process for the uniform distribution of a drug on a granulated base
US4513008A (en) * 1982-07-30 1985-04-23 The Vinoxen Company, Inc. Virucidal compositions and therapy
US4489026A (en) * 1982-09-07 1984-12-18 The Upjohn Company Process for preparing solid unit dosage forms of ultra-low dose drugs
US4631284A (en) * 1984-11-19 1986-12-23 Mallinckrodt, Inc. Acetaminophen compositions containing low doses of chlorpheniramine maleate, method for preparing same and tablets formed therefrom
US5206244A (en) 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
JPH08208478A (ja) * 1994-10-14 1996-08-13 Japan Energy Corp 抗エイズ薬製剤およびその製造方法
ES2201298T3 (es) * 1996-04-04 2004-03-16 Felix Specht Procedimiento para la obtencion de sistemas pulverulentos de libre fluencia con baja dosificacion y/o directamente compactables.
AU4090697A (en) 1996-09-03 1998-03-26 Bristol-Myers Squibb Company Improved process for preparing the antiviral agent {1s-(1alpha, 3alpha, 4beta)}-2-amino-1,9-dihydro-9-{4-hydroxy-3-(hydroxymethyl)-2 -methylenecyclopentyl}-6h-purin-6-one
MXPA01001507A (es) * 1998-08-10 2003-09-10 Novirio Pharmaceuticals Ltd °l-2'desoxi-nucleosidos para el tratamiento de hepatitis b.
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
GB9820416D0 (en) 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
GB9820417D0 (en) 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
GB9820420D0 (en) 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) * 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
IL150447A0 (en) * 2000-02-29 2002-12-01 Bristol Myers Squibb Co Pharmaceutical compositions containing entecavir

Also Published As

Publication number Publication date
TWI287988B (en) 2007-10-11
CA2401569A1 (en) 2001-09-07
PL366102A1 (en) 2005-01-24
NO324014B1 (no) 2007-07-30
EP1642582A1 (en) 2006-04-05
AU2001229775A1 (en) 2001-09-12
ES2253403T5 (es) 2010-04-22
US20010033864A1 (en) 2001-10-25
SK288008B6 (sk) 2012-10-02
CZ303395B6 (cs) 2012-08-29
HUP0500558A2 (hu) 2005-09-28
CO5261593A1 (es) 2003-03-31
ATE312613T1 (de) 2005-12-15
KR20020082230A (ko) 2002-10-30
RS51561B (sr) 2011-08-31
JP5921746B2 (ja) 2016-05-24
GEP20053504B (en) 2005-05-10
BRPI0108435B1 (pt) 2019-02-05
BR0108435A (pt) 2004-06-15
HRP20020649A2 (en) 2004-12-31
JP5140222B2 (ja) 2013-02-06
AR027965A1 (es) 2003-04-16
EG24408A (en) 2009-05-20
NO20024099L (no) 2002-08-28
BG65815B1 (bg) 2010-01-29
SI1267880T1 (sl) 2006-06-30
DK1267880T3 (da) 2006-03-06
SI1267880T2 (sl) 2010-04-30
BRPI0108435B8 (pt) 2021-05-25
DE60115870T2 (de) 2006-08-17
CA2401569C (en) 2009-08-18
JP2012255017A (ja) 2012-12-27
HUP0500558A3 (en) 2012-08-28
DE60115870D1 (de) 2006-01-19
EA200200812A1 (ru) 2003-12-25
MXPA02008359A (es) 2003-02-12
EA006181B1 (ru) 2005-10-27
PL201411B1 (pl) 2009-04-30
NZ520024A (en) 2005-03-24
HK1048771A1 (zh) 2003-04-17
SK11652002A3 (sk) 2003-09-11
DK1267880T4 (da) 2010-05-17
YU63002A (sh) 2005-03-15
WO2001064221A1 (en) 2001-09-07
ES2253403T3 (es) 2006-06-01
US6627224B2 (en) 2003-09-30
EP1267880A1 (en) 2003-01-02
EP1267880B2 (en) 2010-01-20
IL150447A0 (en) 2002-12-01
MY127422A (en) 2006-11-30
EP1267880B1 (en) 2005-12-14
KR100757155B1 (ko) 2007-09-07
JP2015178523A (ja) 2015-10-08
JP2004503467A (ja) 2004-02-05
HU230698B1 (hu) 2017-09-28
DE60115870T3 (de) 2010-07-29
NO20024099D0 (no) 2002-08-28
BG106905A (bg) 2003-04-30
PE20020770A1 (es) 2002-09-06
UA84534C2 (uk) 2008-11-10
EE05442B1 (et) 2011-08-15

Similar Documents

Publication Publication Date Title
EE200200484A (et) Väikeseannuseline entekaviiripreparaat ja selle kasutamine
ID30590A (id) Celana sekali pakai jenis-celana pendek
EE04452B1 (et) Farmatseutiliselt aktiivne morfolinool ja selle kasutamine
EE200300145A (et) Asa- ja polüasanaftalenüülkarboksamiidid ja farmatseutiline kompositsioon
EE04565B1 (et) Adamantaani derivaadid, nende saamine ja kasutamine
ID26056A (id) Popok sekali pakai
ID26389A (id) Popok sekali pakai
DE60114215D1 (de) Kondensierte pyrrolocarbazole gegen entzündungen
EE200200251A (et) Uued N-asabitsükloamiidi derivaadid ja nende kasutamine
EE05507B1 (et) Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
EE200200341A (et) Asendatud oksasolidinoonid ja nende kasutamine
NO20023616D0 (no) Ny anvendelse
EE04879B1 (et) Sünteetilised pindaktiivsed peptiidid ja nende kasutamine sünteetilise surfaktandi valmistamiseks
AR028622A1 (es) Derivados de tropano utiles en terapia
IS6686A (is) Hýdrógel-drifið lyfjaskömmtunarform
BRPI0208558A2 (pt) preparado de combinação de estrogênio-gestagênio e uso
EE04490B1 (et) Ühend, selle valmistamise meetod ning kasutamine meditsiinis
GB0101035D0 (en) Formulation and use thereof
FI20000818A0 (fi) Dermatologinen käyttö ja valmiste
FI20001715A0 (fi) Rankoihin liittyvät järjestelyt ja menetelmät
ID24782A (id) Popok sekali pakai
HK1040196A1 (zh) 低劑量艾替開韋製劑及其應用
DE60117096D1 (de) Dihydroindol- und tetrahydrochinolinderivate
EE200200096A (et) IREN-valk, selle valmistamine ja kasutamine
EE200300466A (et) Püridoindolooni derivaatide kasutamine ravimite valmistamiseks

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
HE1A Change of address